



# Notice of Interim Results

September 6, 2016

Released : September 06, 2016 07:00

RNS Number : 0077J

MaxCyte, Inc.

06 September 2016

MaxCyte, Inc.  
("MaxCyte" or the "Company")

## Notice of Half Year Results

**Maryland, USA - 06 September 2016:** MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, will be announcing its results for the half year ended 30 June 2016 on Tuesday, 27 September 2016.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11.00am BST on the day of the results at the offices of Panmure Gordon & Co., One New Change, London, EC4M 9AF.

**For further information please contact:**

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

*Nominated Adviser and Broker*

+44 (0) 20 7886 2500

**Panmure Gordon**

Freddy Crossley (Corporate Finance)

Fabien Holler

Duncan Monteith  
Tom Salvesen (Corporate Broking)

*Financial PR Advisor*  
Consilium Strategic Communications

+44 (0)203 709 5700  
[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Mary-Jane Elliott  
Chris Welsh  
Lindsey Neville

### **About MaxCyte**

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit <http://www.maxcyte.com/>

This information is provided by RNS  
The company news service from the London Stock Exchange

END

NORUGUAWBUPQGQA